Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study

Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study

Abstract Background Proton-pump inhibitors (PPIs) are the most effective drugs for treating acid-related disorders. However, once-daily dosing with conventional PPIs fail to fully control acid secretion over 24 h. This study aimed to compare the efficacy and safety of HIP1601 (dual delayed-release e...

Full description

Bibliographic Details
Main Authors: Hyun Lim, Jong Kyu Park, Hyunsoo Chung, Si Hyung Lee, Jae Myung Park, Jung Ho Park, Gwang Ha Kim, Sung Kwan Shin, Su Jin Hong, Kwang Jae Lee, Moo In Park, Hye-Kyung Jung, Hyun-Soo Kim, Jae Kyu Sung, Seong Woo Jeon, Suck Chei Choi, Jeong Seop Moon, Nayoung Kim, Jong-Jae Park, Sung Hee Hong, Na Young Kim, Hwoon-Yong Jung
Format: Article
Language:English
Published: BMC 2023-12-01
Series:BMC Gastroenterology
Subjects:
Proton pump inhibitor
HIP1601
Esomeprazole
Gastroesophageal reflux disease
Online Access:https://doi.org/10.1186/s12876-023-03087-6

Internet

https://doi.org/10.1186/s12876-023-03087-6

Similar Items